Patents by Inventor Zhiwu JIANG

Zhiwu JIANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENGINEERED IMMUNE KILLER CELL, PREPARATION METHOD THEREFOR AND USE THEREOF
    Publication number: 20230055186
    Abstract: Disclosed are an engineered immune killer cell, and a preparation method therefor and the use thereof. The engineered immune killer cell is prepared by inducing reprogrammed human T cell, retains the marker and function of the human T cell from which the engineered immune killer cell is derived, has the marker and function of an NK cell, and transfects and expresses, in an obtained immune killer lymphocyte, a CAR molecule which recognizes tumor and virus-associated antigens or a TCR molecule which specifically recognizes a tumor.
    Type: Application
    Filed: September 28, 2020
    Publication date: February 23, 2023
    Inventors: Peng LI, Zhiwu JIANG, Zhaoyang TANG, Le QIN, Rui LIAO, Diwei ZHENG, Yuanbin CUI, Yao YAO, Simiao LIN
  • ENGINEERED HUMAN IMMUNE CELLS, PREPARATION METHOD AND APPLICATION THEREOF
    Publication number: 20220325246
    Abstract: Provided are engineered human immune cells, a preparation method, and an application thereof. The engineered human immune cells are immune killer lymphocytes induced by reprogramming human T cells, from which the BCL11B gene is deleted. The engineered human immune cells retain markers and functions of the T cells from which they are derived and have markers and functions of NK cells. The reprogrammed engineered human immune cells can be used to prepare drugs for treating tumors and infectious diseases.
    Type: Application
    Filed: September 27, 2020
    Publication date: October 13, 2022
    Inventors: Peng LI, Zhiwu JIANG, Zhaoyang TANG, Le QIN, Rui LIAO, Diwei ZHENG, Yuanbin CUI, Simiao LIN, Yao YAO
  • GENETICALLY MODIFIED IMMUNE CELL, PREPARATION METHOD THEREFOR, AND APPLICATION
    Publication number: 20220185858
    Abstract: Provided are a genetically modified immune cell, a preparation method therefor, and an application. The immune cell overexpresses HIL-6 and/or L-GP130. HIL-6 or L-GP130 continuous overexpression/conditionally induced overexpression in the immune cell reduces the side effects of CAR-T therapy while maintaining immune and anti-tumour effects, and has potential value in the treatment of malignant tumours and AIDS.
    Type: Application
    Filed: May 6, 2020
    Publication date: June 16, 2022
    Applicant: SHENZHEN IN VIVO BIOMEDICINE TECHNOLOGY LIMITED COMPANY
    Inventors: Peng LI, Zhiwu JIANG, Zhaoyang TANG, Rui LIAO, Xiaohan HUANG, Simiao LIN, Suna WANG, Youguo LONG, Qiting WU, Yao YAO